Shares of SpringWorks Therapeutics SWTX have rallied 32.9% in the past three months compared with the industry’s increase of 2.7%. Here, we discuss the reasons for the same. Strong Launch of SWTX's ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck KGaA has agreed to buy biotechnology company ...

SpringWorks Therapeutics Inc . (NASDAQ:SWTX), a biotechnology company with a market capitalization of $2.66 billion focused on developing targeted therapies for patients with severe rare diseases and ...

SpringWorks Therapeutics (NASDAQ:SWTX) advanced 6.3% amid takeover speculation. The biotech firm is said to be at the center of renewed takeover speculation, according to a Betaville "uncooked" alert ...

6 analysts have expressed a variety of opinions on SpringWorks Therapeutics (NASDAQ:SWTX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table ...

Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation ...

In the last three months, 6 analysts have published ratings on SpringWorks Therapeutics (NASDAQ:SWTX), offering a diverse range of perspectives from bullish to bearish. The table below provides a ...

SpringWorks Therapeutics has received FDA approval for Nirogacestat, marking its entry into the commercial stage biotech industry. The company is now facing the challenge of successfully ...

The latest price target for SpringWorks Therapeutics (NASDAQ:SWTX) was reported by Guggenheim on May 12, 2025. The analyst firm set a price target for $47.00 expecting SWTX to rise to within 12 months ...

Salad days: Lisbon’s Springworks is booming on a diet of lettuce and fish After just seven years, the aquaponics operation run by a 26-year-old Bowdoin grad is the largest in New England and raises 1 ...